Hubei Dinglong Co Ltd

Hubei Dinglong Co Ltd maintains a capital structure with a debt-to-equity ratio of 0.38, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 2.28, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, the company's return on equity (ROE) is 3.26%, and return on assets (ROA) is 1.96%, both of which are below the typical thresholds for strong performance in the specialty chemicals industry. The gross profit margin is 45.54%, and the operating margin is 23.39%, which are in line with industry norms but do not indicate exceptional profitability.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The company's revenue for the latest period is 810.83 million CNY, with no segment-specific revenue breakdown provided.

Looking ahead, the company's growth trajectory is uncertain. Analysts have provided a mean price target of 46.65 CNY, significantly below the current market price of 79.55 CNY. The mean recommendation is 1.43, indicating a generally positive outlook, but the wide range of price targets (42.00 to 51.30 CNY) suggests a lack of consensus among analysts.

The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a low probability of dilution, but the company's high price-to-earnings ratio of 553.47 and price-to-book ratio of 18.05 suggest that the stock is currently overvalued relative to its fundamentals. The company's capital expenditures are negative, indicating a reduction in investment, which may affect long-term growth prospects.

Recent events, including the latest financial filings, show a decline in operating cash flow and a significant capital expenditure outflow. These developments may impact the company's ability to fund operations and invest in future growth.

Revenue grew 11.6% CAGR over four years, demonstrating consistent top-line expansion in the specialty chemicals sector.

Net income surged 38.3% year-over-year in FY2026, significantly outpacing revenue growth and indicating strong operational leverage.

Free cash flow turned positive in FY2026, reaching 142.3 million CNY after years of negative cash generation.

Cash conversion ratio of 2.5 exceeds the 75th percentile of the specialty chemicals cohort, highlighting superior efficiency.

Long-term debt ballooned to 1.62 billion CNY in FY2025, nearly doubling from the previous year and raising solvency concerns.

The company carries a high credit risk flag, suggesting potential difficulties in meeting financial obligations or refinancing debt.

Debt-to-equity ratio of 0.38 exceeds the 0.23 cohort median, reflecting higher financial leverage than peer companies.

Revenue ¥3.66B, +9,7% YoY; Operating income +26,6% YoY.

• ▍Revenue ¥3.66B, +9,7% YoY
• ▍Operating income +26,6% YoY
• ▍Net income +38,3% YoY
• ▍Free cash flow +813,1% YoY
• ▍Net margin 19.7%

Revenue ¥3.34B, +25,1% YoY; Operating income +125,5% YoY.

• ▍Revenue ¥3.34B, +25,1% YoY
• ▍Operating income +125,5% YoY
• ▍Net income +134,5% YoY
• ▍Free cash flow +102,5% YoY
• ▍Net margin 15.6%

Revenue ¥2.67B, −2,0% YoY; Operating income −34,0% YoY.

• ▍Revenue ¥2.67B, −2,0% YoY
• ▍Operating income −34,0% YoY
• ▍Net income −43,1% YoY
• ▍Free cash flow −630,1% YoY
• ▍Net margin 8.3%

Revenue ¥2.72B, +15,5% YoY; Operating income +66,8% YoY.

• ▍Revenue ¥2.72B, +15,5% YoY
• ▍Operating income +66,8% YoY
• ▍Net income +82,7% YoY
• ▍Free cash flow −195,7% YoY
• ▍Net margin 14.3%

Revenue ¥2.36B; Operating income ¥288.4M.

• ▍Revenue ¥2.36B
• ▍Operating income ¥288.4M
• ▍Net margin 9.1%